In an interview with reporters, GlaxoSmithKline chief executive officer Andrew Witty addressed the record $3 billion in penalties recently assessed against his company – including the question of whether jail time for company executives might be appropriate in such cases.
In a blog entry about the interview, the Philadelphia Inquirer’s David Sell mentions that Witty became CEO in May 2008, which is after the criminal conduct involved in the plea agreement. The GSK board of directors was aware of the investigation ...
continue reading...